ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.85 USD
+0.01 (0.35%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $2.86 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADCT 2.85 +0.01(0.35%)
Will ADCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADCT
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
ADCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
Other News for ADCT
ADC Therapeutics SA 2024 Q2 - Results - Earnings Call Presentation
ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript
RBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)
ADC Therapeutics: A Strong Buy on Robust Trials and Solid Financials
ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript Highlights: Revenue Decline and ...